Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1965
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 2
1967 2
1968 1
1969 1
1971 4
1972 1
1973 1
1977 2
1978 1
1980 3
1981 4
1982 2
1984 2
1985 3
1986 1
1989 2
1990 4
1991 3
1992 3
1993 1
1994 4
1995 3
1996 6
1997 3
1998 1
1999 5
2000 3
2001 4
2002 10
2003 13
2004 11
2005 7
2006 7
2007 11
2008 11
2009 8
2010 11
2011 11
2012 12
2013 11
2014 11
2015 17
2016 10
2017 14
2018 13
2019 21
2020 15
2021 21
2022 27
2023 37
2024 35
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

375 results

Results by year

Filters applied: . Clear all
Page 1
Myonectin protects against skeletal muscle dysfunction in male mice through activation of AMPK/PGC1α pathway.
Ozaki Y, Ohashi K, Otaka N, Kawanishi H, Takikawa T, Fang L, Takahara K, Tatsumi M, Ishihama S, Takefuji M, Kato K, Shimizu Y, Bando YK, Inoue A, Kuzuya M, Miura S, Murohara T, Ouchi N. Ozaki Y, et al. Among authors: takahara k. Nat Commun. 2023 Aug 4;14(1):4675. doi: 10.1038/s41467-023-40435-2. Nat Commun. 2023. PMID: 37542026 Free PMC article.
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
Komura K, Hirosuna K, Tokushige S, Tsujino T, Nishimura K, Ishida M, Hayashi T, Ura A, Ohno T, Yamazaki S, Nakamori K, Kinoshita S, Maenosono R, Ajiro M, Yoshikawa Y, Takai T, Tsutsumi T, Taniguchi K, Tanaka T, Takahara K, Konuma T, Inamoto T, Hirose Y, Ono F, Shiraishi Y, Yoshimi A, Azuma H. Komura K, et al. Among authors: takahara k. Mol Cancer. 2023 Nov 18;22(1):185. doi: 10.1186/s12943-023-01897-6. Mol Cancer. 2023. PMID: 37980528 Free PMC article.
Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab.
Komura K, Tokushige S, Ishida M, Hirosuna K, Yamazaki S, Nishimura K, Ajiro M, Ohno T, Nakamori K, Kinoshita S, Tsujino T, Maenosono R, Yoshikawa Y, Takai T, Tsutsumi T, Taniguchi K, Tanaka T, Takahara K, Inamoto T, Hirose Y, Ono F, Shiraishi Y, Yoshimi A, Azuma H. Komura K, et al. Among authors: takahara k. Cancer Sci. 2023 Dec;114(12):4622-4631. doi: 10.1111/cas.15976. Epub 2023 Sep 26. Cancer Sci. 2023. PMID: 37752769 Free PMC article.
Interlaboratory evaluation of LC-MS-based biomarker assays.
Saito K, Goda R, Arai K, Asahina K, Kawabata M, Uchiyama H, Andou T, Shimizu H, Takahara K, Kakehi M, Yamauchi S, Nitta SI, Suga T, Fujita H, Ishikawa R, Saito Y. Saito K, et al. Among authors: takahara k. Bioanalysis. 2024 Mar;16(6):389-402. doi: 10.4155/bio-2023-0173. Epub 2024 Feb 9. Bioanalysis. 2024. PMID: 38334082 Review.
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.
Tsujino T, Tokushige S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Ohno T, Nakamori K, Maenosono R, Nishimura K, Yamazaki S, Uchimoto T, Yanagisawa T, Mori K, Urabe F, Tsuzuki S, Iwatani K, Yamamoto S, Takahara K, Inamoto T, Kimura T, Ohno Y, Shiroki R, Azuma H. Tsujino T, et al. Among authors: takahara k. Cancer Med. 2023 Oct;12(19):19414-19422. doi: 10.1002/cam4.6536. Epub 2023 Sep 14. Cancer Med. 2023. PMID: 37706578 Free PMC article.
Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma.
Tsujino T, Komura K, Inamoto T, Maenosono R, Hashimoto T, Adachi T, Hirasawa Y, Tokushige S, Ohno T, Yamazaki S, Fukushima T, Nakamura K, Yano Y, Nishimura K, Kinoshita S, Nakamori K, Tsutsumi T, Matsunaga T, Yoshikawa Y, Uchimoto T, Takai T, Minami K, Uehara H, Hirano H, Nomi H, Takahara K, Ohno Y, Azuma H. Tsujino T, et al. Among authors: takahara k. World J Urol. 2023 Dec;41(12):3585-3591. doi: 10.1007/s00345-023-04687-3. Epub 2023 Nov 4. World J Urol. 2023. PMID: 37924336
Boron neutron capture therapy for urological cancers.
Takahara K, Miyatake SI, Azuma H, Shiroki R. Takahara K, et al. Int J Urol. 2022 Jul;29(7):610-616. doi: 10.1111/iju.14855. Epub 2022 Mar 3. Int J Urol. 2022. PMID: 35240726 Review.
Mechanistic insights into lethal hyper progressive disease induced by PD-L1 inhibitor in metastatic urothelial carcinoma.
Nishimura K, Takahara K, Komura K, Ishida M, Hirosuna K, Maenosono R, Ajiro M, Sakamoto M, Iwatsuki K, Nakajima Y, Tsujino T, Taniguchi K, Tanaka T, Inamoto T, Hirose Y, Ono F, Kondo Y, Yoshimi A, Azuma H. Nishimura K, et al. Among authors: takahara k. NPJ Precis Oncol. 2024 Sep 17;8(1):206. doi: 10.1038/s41698-024-00707-6. NPJ Precis Oncol. 2024. PMID: 39289546 Free PMC article.
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y, Adachi T, Hashimoto T, Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, Nishimura K, Takahara K, Saruta M, Fujita K, Hashimoto M, Uemura H, Shiroki R, Azuma T, Kimura T, Ohno Y. Hirasawa Y, et al. Among authors: takahara k. J Cancer Res Clin Oncol. 2024 Apr 9;150(4):182. doi: 10.1007/s00432-024-05717-2. J Cancer Res Clin Oncol. 2024. PMID: 38592548 Free PMC article.
375 results